aliskiren + valsartan + chlorthalidone

**aliskiren + valsartan + chlorthalidone** is a theoretical fixed-dose combination antihypertensive regimen combining three agents with complementary mechanisms. - **Aliskiren** is a direct renin inhibitor that blocks the conversion of angiotensinogen to angiotensin I, reducing the downstream effects of the renin-angiotensin-aldosterone system (RAAS) and lowering blood pressure by decreasing vasoconstriction and aldosterone-mediated volume expansion[1]. - **Valsartan** is an angiotensin II receptor blocker (ARB), selectively antagonizing the angiotensin II type 1 (AT1) receptor, thus preventing vasoconstriction and aldosterone release, further reducing blood pressure[3]. - **Chlorthalidone** is a thiazide-like diuretic, similar in mechanism to hydrochlorothiazide but with a longer half-life and more potent effect, promoting renal excretion of sodium and water to decrease plasma volume and lower blood pressure[1]. This combination is designed for patients with hypertension inadequately controlled by monotherapy or two-drug regimens, targeting multiple pathways involved in blood pressure regulation. While other triple combinations with similar classes (such as amlodipine + valsartan + hydrochlorothiazide) are FDA-approved, there is no current evidence for FDA approval or marketed products specifically containing aliskiren + valsartan + chlorthalidone[4]. Aliskiren + valsartan (Valturna) was previously marketed but discontinued in 2012 due to safety concerns, especially in patients with diabetes and renal impairment[2]. Chlorthalidone is favored in some large outcome trials due to superior efficacy over hydrochlorothiazide[1].